Justices Asked To Keep Staying Novartis' Gilenya IP Loss
Novartis has urged the U.S. Supreme Court to continue blocking a Federal Circuit mandate invalidating its patent on multiple sclerosis drug Gilenya, arguing that the stay petition is not just an...To view the full article, register now.
Already a subscriber? Click here to view full article